226 related articles for article (PubMed ID: 35726553)
21. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.
Fu L; Wang G; Shevchuk MM; Nanus DM; Gudas LJ
Cancer Res; 2011 Nov; 71(21):6848-56. PubMed ID: 21908555
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
23. TRIB3 increases cell resistance to arsenite toxicity by limiting the expression of the glutathione-degrading enzyme CHAC1.
Örd D; Örd T; Biene T; Örd T
Biochim Biophys Acta; 2016 Nov; 1863(11):2668-2680. PubMed ID: 27526673
[TBL] [Abstract][Full Text] [Related]
24. Obesity challenges the hepatoprotective function of the integrated stress response to asparaginase exposure in mice.
Nikonorova IA; Al-Baghdadi RJT; Mirek ET; Wang Y; Goudie MP; Wetstein BB; Dixon JL; Hine C; Mitchell JR; Adams CM; Wek RC; Anthony TG
J Biol Chem; 2017 Apr; 292(16):6786-6798. PubMed ID: 28242759
[TBL] [Abstract][Full Text] [Related]
25. GCN2- and eIF2α-phosphorylation-independent, but ATF4-dependent, induction of CARE-containing genes in methionine-deficient cells.
Mazor KM; Stipanuk MH
Amino Acids; 2016 Dec; 48(12):2831-2842. PubMed ID: 27613409
[TBL] [Abstract][Full Text] [Related]
26. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
27. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
28. Deficiency of the X-inactivation escaping gene
Zheng Q; Li P; Zhou X; Qiang Y; Fan J; Lin Y; Chen Y; Guo J; Wang F; Xue H; Xiong J; Li F
Theranostics; 2021; 11(18):8674-8691. PubMed ID: 34522206
[No Abstract] [Full Text] [Related]
29. NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.
Kubala JM; Laursen KB; Schreiner R; Williams RM; van der Mijn JC; Crowley MJ; Mongan NP; Nanus DM; Heller DA; Gudas LJ
Cancer Biol Ther; 2023 Dec; 24(1):2170669. PubMed ID: 36722045
[TBL] [Abstract][Full Text] [Related]
30. Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.
Tóth K; Chintala S; Rustum YM
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):642-7. PubMed ID: 25046225
[TBL] [Abstract][Full Text] [Related]
31. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.
Hoefflin R; Harlander S; Schäfer S; Metzger P; Kuo F; Schönenberger D; Adlesic M; Peighambari A; Seidel P; Chen CY; Consenza-Contreras M; Jud A; Lahrmann B; Grabe N; Heide D; Uhl FM; Chan TA; Duyster J; Zeiser R; Schell C; Heikenwalder M; Schilling O; Hakimi AA; Boerries M; Frew IJ
Nat Commun; 2020 Aug; 11(1):4111. PubMed ID: 32807776
[TBL] [Abstract][Full Text] [Related]
32. A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.
Liu R; Feng Y; Deng Y; Zou Z; Ye J; Cai Z; Zhu X; Liang Y; Lu J; Zhang H; Luo Y; Han Z; Zhuo Y; Xie Q; Hon CT; Liang Y; Wu CL; Zhong W
J Exp Clin Cancer Res; 2021 Jun; 40(1):188. PubMed ID: 34098990
[TBL] [Abstract][Full Text] [Related]
33. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
34. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.
Teng R; Liu Z; Tang H; Zhang W; Chen Y; Xu R; Chen L; Song J; Liu X; Deng H
Redox Biol; 2019 Jun; 24():101218. PubMed ID: 31112866
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
36. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
37. Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.
Fu L; Minton DR; Zhang T; Nanus DM; Gudas LJ
Mol Cancer Res; 2015 May; 13(5):870-8. PubMed ID: 25715653
[TBL] [Abstract][Full Text] [Related]
38. Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.
Minton DR; Fu L; Mongan NP; Shevchuk MM; Nanus DM; Gudas LJ
Clin Cancer Res; 2016 Jun; 22(11):2791-801. PubMed ID: 26783287
[TBL] [Abstract][Full Text] [Related]
39. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
40. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
